What are AXIN2 antibodies?
Anti-AXIN2 antibodies are immunoglobulins that specifically recognize and bind AXIN2, an inhibitor of the Wnt signaling pathway in humans. In research applications, these antibodies are used to detect AXIN2 in tissue samples, cell lysates, and cultured cells. AXIN2 down-regulates beta-catenin by facilitating its phosphorylation together with APC and GSK3B, forming part of the beta-catenin destruction complex that keeps Wnt signaling in check in the resting state. Detecting AXIN2 supports research into Wnt pathway activity in development, tissue regeneration, and cancer, where AXIN2 also serves as a canonical Wnt target gene readout.
Catalog highlights and purchasing considerations
About the Biocompare AXIN2 antibody catalog
The Biocompare antibody search tool lists anti-AXIN2 antibodies from a range of suppliers, spanning unconjugated and fluorophore- or enzyme-conjugated formats. Western blot is the most common validated application among these listings, followed by immunohistochemistry and immunofluorescence. Several AXIN2 antibodies mentioned here have been cited across a range of developmental biology research, including brain-targeted delivery of a Wnt inhibitor for autism-associated social deficits, Wnt/β-catenin-mediated fibroblast transformation induced by IL-17A, and DKK1-targeted corneal nerve regeneration. Antibody reviews written by individual researchers have discussed unique immunodetection studies involving AXIN2, such as validated use in western blotting.
Considerations when choosing an AXIN2 antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.